VP4-2021: EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9: Interim analysis of phase III trial of cemiplimab vs. investigator's choice (IC) chemotherapy (chemo) in recurrent/metastatic (R/M)... von Tewari, K.S., Monk, B.J., Vergote, I., Miller, A., de Melo, A.C., Kim, H.S., Kim, Y.M., Lisyanskaya, A., Samouëlian, V., Lorusso, D., Damian, F., Chang, C-L., Gotovkin, E.A., Takahashi, S., Ramone, D., Pikiel, J., Li, J., Mathias, M., Fury, M.G., Oaknin, A.

Volltext

783P Impact of cemiplimab on quality of life (QoL), functioning and symptoms in patients (pts) with recurrent/metastatic (R/M) cervical carcinoma: Results from EMPOWER-Cervical 1/G... von Oaknin, A., Monk, B.J., Vergote, I., de Melo, A.C., Kim, Y.M., Lisyanskaya, A., Samouëlian, V., Kim, H.S., Gotovkin, E.A., Damian, F., Chang, C-L., Takahashi, S., Li, J., Mathias, M., Fury, M.G., Ivanescu, C., Reaney, M., Harnett, J., Chen, C-I., Tewari, K.S.

Volltext

Survival with Cemiplimab in Recurrent Cervical Cancer von Tewari, K.S, Monk, B.J, Vergote, I, Miller, A, de Melo, A.C, Kim, H.-S, Kim, Y.M, Lisyanskaya, A, Samouelian, V, Lorusso, D, Damian, F, Chang, C.-L, Gotovkin, E.A, Takahashi, S, Ramone, D, Pikiel, J, Mackowiak-Matejczyk, B, Alia, E.M. Guerra, Colombo, N, Makarova, Y, Rischin, D, Lheureux, S, Hasegawa, K, Fujiwara, K, Li, J, Jamil, S, Jankovic, V, Chen, C, Seebach, F, Weinreich, D.M, Yancopoulos, G.D, Lowy, I, Mathias, M, Fury, M.G, Oaknin, A

Volltext

VP4-2021: EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9: Interim analysis of phase III trial of cemiplimab vs. investigator's choice (IC) chemotherapy (chemo) in recurrent/metastatic (R/M)... von Tewari, K.S, Monk, B.J, Vergote, I, Miller, A, de Melo, A.C, Kim, H.S, Kim, Y.M, Lisyanskaya, A, Samouelian, V, Lorusso, D, Damian, F, Chang, C.-L, Gotovkin, E.A, Takahashi, S, Ramone, D, Pikiel, J, Li, J, Mathias, M, Fury, M.G, Oaknin, A

Volltext